Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Shingrix

Top Research in Rheumatoid Arthritis Presented at ACR Convergence 2024

Jeffrey Curtis, MD, MS, MPH  |  December 3, 2024

Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…

Filed under:ACR ConvergenceConditionsGuidanceMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 RA

All That Is Old—& New: Treatment Implications for Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  November 7, 2023

EULAR 2023 (MILAN)—Over the past several years, a plethora of new treatments for patients with rheumatoid arthritis (RA) has emerged, while older treatments still play a large role in therapy for many patients. At the EULAR 2023 session titled Rheumatoid Arthritis: New Small Molecules and Old DMARDs, several speakers presented abstracts comparing different treatment effects…

Filed under:Meeting ReportsRheumatoid Arthritis Tagged with:EULAR 2023RA Resource CenterRheumatoid Arthritis (RA)

A World of Difference: Updates from the Global Rheumatology Summit

Jason Liebowitz, MD, FACR  |  January 20, 2023

The second annual Global Rheumatology Summit focused on climate change, conflict and migration, as well as other global issues in rheumatology.

Filed under:ACR ConvergenceConditionsMeeting ReportsMyositis Tagged with:ACR Convergence 2022Global Rheumatology Summitidiopathic inflammatory myositisMentorshippatient accessWorkforce

A Shot of Wisdom: Vaccinations in Patients with Rheumatic Disease

Jason Liebowitz, MD, FACR  |  December 2, 2022

PHILADELPHIA—The treatment of rheumatic diseases is often a double-edged sword: immunosuppressive regimens can be very effective in reducing disease activity, but the cost of such treatments may be seen in the form of increased risk of infection. At ACR Convergence 2022, the session titled ACR Guidelines for Vaccination in Patients with Rheumatic and Musculoskeletal Diseases…

Filed under:ACR ConvergenceClinical Criteria/GuidelinesConditionsMeeting Reports Tagged with:ACR Convergence 2022COVID-19vaccination

The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?

Jason Liebowitz, MD, FACR  |  November 9, 2020

ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…

Filed under:ACR ConvergenceDrug UpdatesMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2020ACR Convergence 2020 – RA

Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib

Lisa Rapaport  |  April 21, 2020

(Reuters Health)—The live herpes zoster vaccine does not provide reliable long-term protection in rheumatoid arthritis (RA) patients taking tofacitinib, a recent study suggests. Current ACR guidelines conditionally recommend that patients with RA who are 50 years and older be vaccinated against herpes zoster prior to starting therapy with the Janus kinase (JAK) inhibitor tofacitinib or…

Filed under:ConditionsRheumatoid Arthritis Tagged with:herpes zosterRheumatoid Arthritis (RA)shinglesShingrixTofacitinibvaccine

Expert Says Vaccines Are Largely Safe for Rheumatology Patients

Thomas R. Collins  |  July 18, 2019

CHICAGO—Rheumatologists often come to Brian Schwartz, MD, associate professor of medicine and vice chief for clinical affairs in the Division of Infectious Diseases, University of California, San Francisco, with a concern: A patient on immunosuppression has a family member who needs a live vaccine, but the patient may be vulnerable to the vaccine’s effects. Should…

Filed under:ConditionsPractice Support Tagged with:vaccinationvaccines

Vaccines & Rheumatology Patients

Thomas R. Collins  |  June 12, 2019

Vaccines are often safe for rheumatology patients, but precautions may be needed, said Brian Schwartz, MD, at the 2019 ACR State-of-the-Art Clinical Symposium…

Filed under:Conditions Tagged with:2019 State-of-the-Art Clinical Symposiumpatient carevaccinationvaccines

At Vasculitis Conference, Patients Share Hope, Humor & Hardships

Bryn Nelson, PhD  |  April 15, 2019

SEATTLE—At the first regional vasculitis patient conference ever held in the Pacific Northwest, a panoramic view of Mt. Rainier on a clear January morning set the tone for a day of optimistic talks about recent successes against the various forms of blood vessel inflammation. One attendee at the Jan. 12 conference, sponsored by the Vasculitis…

Filed under:Patient PerspectiveVasculitis Tagged with:vasculitis research

Zoster Reactivation Risk in Patients Treated with Cyclophosphamide

Susan Bernstein  |  December 18, 2018

Varicella-zoster-virus (VZV) reactivation, which can cause patients to develop herpes zoster (i.e., shingles), occurs more frequently in patients with systemic vasculitis and systemic lupus erythematosus (SLE) who have received intravenous cyclophosphamide than in otherwise healthy adults, according to a retrospective study published in The Journal of Rheumatology by researchers in France.1 The study also shows…

Filed under:ConditionsResearch RheumSystemic Lupus ErythematosusVasculitis Tagged with:cyclophosphamideherpes zostershinglesvalacyclovir

  • 1
  • 2
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences